1. Is Healthcare Global Enterprises Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a below average quality company.
2. Is Healthcare Global Enterprises Ltd undervalued or overvalued?
The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Healthcare Global Enterprises Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||2.7%||-2.6%||4.6%||4.1%||4.4%||4.3%||2.1%||-1%||-9.5%||1.8%||-|
|Value Creation Index ⓘ||-0.8||-1.2||-0.7||-0.7||-0.7||-0.7||-0.9||-1.1||-1.7||-0.9||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||30.3%||15.4%||12.5%||19.9%||18.4%||17.8%||11.9%||-7.6%||38.2%||-|
|Adj EPS ⓘ||-0.9||-5.5||0.5||0.3||2.4||1.5||-2.9||-12.2||-15.4||-3.3||-1.9|
|YoY Gr. Rt. %||-||NA||NA||-42.6%||680.7%||-40.1%||-298.6%||NA||NA||NA||-|
|BVPS (₹) ⓘ||43.5||38.2||39.3||50||50.3||55.4||53.6||42.2||51.6||62.1||63.4|
|Adj Net Profit ⓘ||-6.1||-37.6||3.8||2.7||20.7||12.6||-25.3||-108||-193||-45.8||-26|
|Cash Flow from Ops. ⓘ||28.6||49.6||59.7||73.2||91.3||97.8||98.5||130||121||220||-|
|Debt/CF from Ops. ⓘ||10.8||5.4||5.8||4.4||4.6||4.7||6.7||5.5||3.9||1.9||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||-206.4%||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-2.4||-13.5||1.4||0.8||4.8||2.7||-5.1||-25.1||-35.9||-5.9||-3|
|Op. Profit Mgn % ⓘ||15||8.2||14.7||14.6||15||13.6||12.6||15.5||12.1||16.9||17.6|
|Net Profit Mgn % ⓘ||-1.6||-7.9||1.5||1.1||3.1||1.3||-2.1||-10.5||-21.9||-4.4||-1.7|
|Debt to Equity ⓘ||1.1||1||1.3||0.8||1||1||1.4||1.9||0.7||0.5||0.4|
|Working Cap Days ⓘ||125||112||109||117||126||136||144||151||179||126||113|
|Cash Conv. Cycle ⓘ||-12||-27||-35||-50||-49||-38||-27||-12||0||-10||4|
Sales growth is growing at healthy rate in last 3 years 12.64%
Debt to equity has declined versus last 3 years average to 0.47
Sales growth is good in last 4 quarters at 24.72%
Return on Equity is Poor
|TTM EPS (₹)||-2.5||-1.9|
|TTM Sales (₹ Cr.)||930||1,548|
|BVPS (₹.) ⓘ||80.8||63.4|
|Reserves (₹ Cr.) ⓘ||985||742|
|From the Market|
|52 Week Low / High (₹)||221.05 / 320.00|
|All Time Low / High (₹)||62.95 / 352.00|
|Market Cap (₹ Cr.)||4,238|
|Equity (₹ Cr.)||139.1|
|Face Value (₹)||10|
|Industry PE ⓘ||26.1|
Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.
The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.
The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.
The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.
Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.
Business area of the company
The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.
Major events and milestones
Awards and accreditations